Análisis Argos
WST
WSTCara
West Pharmaceutical Services, Inc. · Healthcare
US$ 365.74
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
56/100
LA RESPUESTA
El mercado le pide crezca 42.9% al año — más de lo que ha demostrado (11.4%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Retorno sobre el capital alto (18%).
Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR1/6FUTURO3/6PASADO4/6SALUD6/6DIVIDENDO2/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO4/6SALUD6/6DIVIDENDO2/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos56de 100Cara
Ingresos6%
US$ 3.1 B
Margen operativo2%
20.1%
Flujo de caja libre68%
US$ 0.5 B
Deuda neta
US$ -0.4 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 25.8B
P/E52.3x
EV/EBITDA34.3x
FCF yield1.8%
ROIC17.7%
Margen operativo20.1%
Crecim. ingresos+6.3%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

prnewswire.com · 1 jul
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026.
zacks.com · 1 jul
MMSI or WST: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Merit Medical (MMSI) and West Pharmaceutical Services (WST). But which of these two stocks offers value investors a better bang for their buck right now?
247wallst.com · 9 jun
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More
Pre-Market Stock Futures: Futures are trading higher after the bulls tried to rally stocks on Monday, after the drubbing they took on Friday, and it looks the same way today. While it was a partial victory on Monday, by the close, the huge gains from the morning were cut in half, and the Dow Jones... Here Are Tuesday's Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More
seekingalpha.com · 8 jun
Top 50 High-Quality Dividend Growth Stocks For June 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.
seekingalpha.com · 2 jun
West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
West Pharmaceutical Services, Inc. (WST) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
fool.com · 2 jun
Billionaire Bill Gates' Foundation Dumped Microsoft but Loaded Up on This Dividend Champion
The Microsoft founder's foundation recently added this healthcare stock to its portfolio.
reuters.com · 1 jun
West Pharma names former Thermo Fisher executive Lagarde as CEO
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel ​Lagarde as its top boss, effective ‌August 31, succeeding longtime chief Eric Green.
prnewswire.com · 1 jun
West Appoints Michel Lagarde to be President and Chief Executive Officer
Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.